To refer to this page use:
|Abstract:||Resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) led the World Health Organization (WHO) to recommend changes in national drug policies. The time between policy changes and their implementation profoundly affects program impact. We developed a model based on data on antimalarial treatments, extracted from household surveys and national antimalarial policy information from the literature. Drug use in each country during the time period 1999–2011 and the trend in reduction of CQ use after policy change were estimated. The SP use estimates were correlated with the prevalence of a molecular marker associated with SP resistance. There was no spatial pattern in the country-level rate of reduction of CQ use, after policy change. In East Africa SP drug use was strongly correlated to resistance. If artemisinin resistance spreads to, or emerges in, Africa this methodology will be a valuable tool to estimate actual drug use and its impact on changes in drug efficacy.|
|Citation:||Flegg, Jennifer A., Gharbi, Myriam, Hopkins Sibley, Carol, Shewchuk, Tanya, Metcalf, C. Jessica E., Guerin, Philippe J., Venkatesan, Meera. (2013). Trends in Antimalarial Drug Use in Africa. The American Journal of Tropical Medicine and Hygiene, 89 (5), 857 - 865. doi:10.4269/ajtmh.13-0129|
|Pages:||857 - 865|
|Type of Material:||Journal Article|
|Journal/Proceeding Title:||The American Journal of Tropical Medicine and Hygiene|
|Version:||Final published version. Article is made available in OAR by the publisher's permission or policy.|
Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.